• Xeris Biopharma CFO Steven Pieper sold 45,000 common shares in two trades on July 6-7, SEC filing shows.
• Sales priced at USD 8.5 on July 6, USD 8.52 weighted average on July 7.
• Directly held stake fell to 1,366,053 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001875714-26-000007), on July 07, 2026, and is solely responsible for the information contained therein.